Interestingly, a synthetic 18 amino-acid peptide derived from the SDC2 ectodomain (SDC2-pep) is sufficient to bind and activate CD148 and use of this peptide has been proposed as a potential therapeutic strategy for idiopathic pulmonary fibrosis [38]. Here, SDC2 is linked to idiopathic pulmonary fibrosis.